FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969544875> ?p ?o ?g. }

• W2969544875 endingPage "2609" @default.
• W2969544875 startingPage "2601" @default.
• W2969544875 abstract "PURPOSE Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficacy of ado-trastuzumab emtansine (T-DM1) plus neratinib in patients who progressed on trastuzumab plus pertuzumab. PATIENTS AND METHODS In this 3 + 3 dose-escalation study, patients with metastatic breast cancer who progressed on trastuzumab, pertuzumab, and a taxane were treated with T-DM1 at 3.6 mg/kg intravenously every 3 weeks and dose-escalating neratinib at 120, 160, 200, or 240 mg/d orally. RESULTS Twenty-seven patients were treated across four dose-levels of neratinib. Dose-limiting toxicity in cycle 1 was grade 3 diarrhea in six patients and grade 3 nausea in one; no patient experienced grade 4 diarrhea, and there were no grade 5 toxicities. Other grade 3 to 4 toxicities included nausea (11%), dehydration (11%), electrolyte abnormality (19%), thrombocytopenia (15%), elevated transaminase levels (7%), and fatigue (7%). Twelve (63%) of 19 evaluable patients had an objective response. Responses occurred at all neratinib doses. Plasma cell–free DNA at baseline showed ERBB2 (HER2) amplification in 10 of 27 patients. Deep and more durable responses occurred in patients with cell-free DNA ERBB2 amplification. Two complete responders had high expression of total HER2 and p95HER2 in baseline tissue. CONCLUSION We report the recommended phase II dose of T-DM1 3.6 mg/kg and neratinib 160 mg/d for this combination. Possible resistance mechanisms to HER2 antibodies may be loss of the HER2 receptor and high expression of p95HER2. These data provide the basis for an ongoing phase II study to better define the activity of this regimen." @default.
• W2969544875 created "2019-08-29" @default.
• W2969544875 creator A5013172168 @default.
• W2969544875 creator A5014411546 @default.
• W2969544875 creator A5016241209 @default.
• W2969544875 creator A5018863416 @default.
• W2969544875 creator A5022192136 @default.
• W2969544875 creator A5027371881 @default.
• W2969544875 creator A5028819039 @default.
• W2969544875 creator A5039905647 @default.
• W2969544875 creator A5049175137 @default.
• W2969544875 creator A5060040445 @default.
• W2969544875 creator A5069843364 @default.
• W2969544875 creator A5079315515 @default.
• W2969544875 creator A5081802864 @default.
• W2969544875 creator A5083386276 @default.
• W2969544875 creator A5083535676 @default.
• W2969544875 creator A5088914288 @default.
• W2969544875 creator A5089382639 @default.
• W2969544875 creator A5089906665 @default.
• W2969544875 date "2019-10-10" @default.
• W2969544875 modified "2023-10-11" @default.
• W2969544875 title "Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10" @default.
• W2969544875 cites W1984007340 @default.
• W2969544875 cites W1987576644 @default.
• W2969544875 cites W2012732226 @default.
• W2969544875 cites W2040935952 @default.
• W2969544875 cites W2071890410 @default.
• W2969544875 cites W2080241329 @default.
• W2969544875 cites W2101299592 @default.
• W2969544875 cites W2101979288 @default.
• W2969544875 cites W2104289405 @default.
• W2969544875 cites W2104816881 @default.
• W2969544875 cites W2114195503 @default.
• W2969544875 cites W2120627364 @default.
• W2969544875 cites W2135890715 @default.
• W2969544875 cites W2140927379 @default.
• W2969544875 cites W2144499620 @default.
• W2969544875 cites W2146384083 @default.
• W2969544875 cites W2149952977 @default.
• W2969544875 cites W2154246971 @default.
• W2969544875 cites W2156953890 @default.
• W2969544875 cites W2159967578 @default.
• W2969544875 cites W2166199281 @default.
• W2969544875 cites W2195930565 @default.
• W2969544875 cites W2264000214 @default.
• W2969544875 cites W2314197930 @default.
• W2969544875 cites W2379981061 @default.
• W2969544875 cites W2443444708 @default.
• W2969544875 cites W2521448810 @default.
• W2969544875 cites W2551307347 @default.
• W2969544875 cites W2596555668 @default.
• W2969544875 cites W2726739357 @default.
• W2969544875 cites W2741016607 @default.
• W2969544875 cites W2800224623 @default.
• W2969544875 cites W2807211107 @default.
• W2969544875 cites W2810342468 @default.
• W2969544875 doi "https://doi.org/10.1200/jco.19.00858" @default.
• W2969544875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6784849" @default.
• W2969544875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31442103" @default.
• W2969544875 hasPublicationYear "2019" @default.
• W2969544875 type Work @default.
• W2969544875 sameAs 2969544875 @default.
• W2969544875 citedByCount "42" @default.
• W2969544875 countsByYear W29695448752020 @default.
• W2969544875 countsByYear W29695448752021 @default.
• W2969544875 countsByYear W29695448752022 @default.
• W2969544875 countsByYear W29695448752023 @default.
• W2969544875 crossrefType "journal-article" @default.
• W2969544875 hasAuthorship W2969544875A5013172168 @default.
• W2969544875 hasAuthorship W2969544875A5014411546 @default.
• W2969544875 hasAuthorship W2969544875A5016241209 @default.
• W2969544875 hasAuthorship W2969544875A5018863416 @default.
• W2969544875 hasAuthorship W2969544875A5022192136 @default.
• W2969544875 hasAuthorship W2969544875A5027371881 @default.
• W2969544875 hasAuthorship W2969544875A5028819039 @default.
• W2969544875 hasAuthorship W2969544875A5039905647 @default.
• W2969544875 hasAuthorship W2969544875A5049175137 @default.
• W2969544875 hasAuthorship W2969544875A5060040445 @default.
• W2969544875 hasAuthorship W2969544875A5069843364 @default.
• W2969544875 hasAuthorship W2969544875A5079315515 @default.
• W2969544875 hasAuthorship W2969544875A5081802864 @default.
• W2969544875 hasAuthorship W2969544875A5083386276 @default.
• W2969544875 hasAuthorship W2969544875A5083535676 @default.
• W2969544875 hasAuthorship W2969544875A5088914288 @default.
• W2969544875 hasAuthorship W2969544875A5089382639 @default.
• W2969544875 hasAuthorship W2969544875A5089906665 @default.
• W2969544875 hasBestOaLocation W29695448751 @default.
• W2969544875 hasConcept C121608353 @default.
• W2969544875 hasConcept C126322002 @default.
• W2969544875 hasConcept C143998085 @default.
• W2969544875 hasConcept C197934379 @default.
• W2969544875 hasConcept C2775930923 @default.
• W2969544875 hasConcept C2777511904 @default.
• W2969544875 hasConcept C2778375690 @default.
• W2969544875 hasConcept C2779413316 @default.
• W2969544875 hasConcept C2779786085 @default.
• W2969544875 hasConcept C2780580376 @default.

• next